Home › Research › Getting a diagnosis
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz C, Mayeux R.. Biochemical pharmacology, 2014-01-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The global prevalence of dementia is as high as 24 million, and has been predicted to quadruple by the year 2050. In the US alone, Alzheimer disease (AD) - the most frequent cause of dementia characterized by a progressive decline in cognitive function in particular the memory domain - causes estimated health-care costs of $ 172 billion per year. Key neuropathological hallmarks of the AD brain are diffuse and neuritic extracellular amyloid plaques - often surrounded by dystrophic neurites - and intracellular neurofibrillary tangles. These pathological changes are frequently accompanied by reactive microgliosis and loss of neurons, white matter and synapses. The etiological mechanisms underlying these neuropathological changes remain unclear, but are probably caused by both environmental and genetic factors. In this review article, we provide an overview of the epidemiology of AD, review the biomarkers that may be used for risk assessment and in diagnosis, and give suggestions for future research.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes how common Alzheimer's disease is, its costs, and its hallmark brain changes of amyloid plaques and neurofibrillary tangles. It states that the underlying causes remain unclear but are probably due to both environmental and genetic factors, and it discusses biomarkers that may be used for risk assessment and diagnosis.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Reitz, C., & Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2013.12.024
Vancouver
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical pharmacology. 2014. doi:10.1016/j.bcp.2013.12.024. PMID: 24398425.
BibTeX
@article{reitz2014-24398425,
author = {Reitz, C. and Mayeux, R.},
title = {{Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers}},
journal = {Biochemical pharmacology},
year = {2014},
doi = {10.1016/j.bcp.2013.12.024},
pmid = {24398425},
url = {https://doi.org/10.1016/j.bcp.2013.12.024}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In the US alone, Alzheimer disease (AD) - the most frequent cause of dementia characterized by a progressive decline in cognitive function in particular the memory domain - causes estimated health-care costs of $ 172 billion per year.
- Key neuropathological hallmarks of the AD brain are diffuse and neuritic extracellular amyloid plaques - often surrounded by dystrophic neurites - and intracellular neurofibrillary tangles.
- These pathological changes are frequently accompanied by reactive microgliosis and loss of neurons, white matter and synapses.
- The etiological mechanisms underlying these neuropathological changes remain unclear, but are probably caused by both environmental and genetic factors.
- In this review article, we provide an overview of the epidemiology of AD, review the biomarkers that may be used for risk assessment and in diagnosis, and give suggestions for future research.
Why it matters
This review describes how common Alzheimer's disease is, its costs, and its hallmark brain changes of amyloid plaques and neurofibrillary tangles. It states that the underlying causes remain unclear but are probably due to both environmental and genetic factors, and it discusses biomarkers that may be used for risk assessment and diagnosis.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biochemical pharmacology) |
| Journal's citation record | 3 / 4 | Biochemical Pharmacology: journal h-index 292 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,181 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 84.4 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 6 / 6 | Cited 74.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 23 other studies in this library |
| Still being cited | 3 / 4 | Cited 181 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Richard P Mayeux: h-index 158 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Columbia University: institution h-index 1,824 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24398425) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 84.
Later studies that cite this one
23 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also in Getting a diagnosis
141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.